Biochemical bone markers in breast cancer

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Summary: Bone metastases, the most common metastatic manifestation of many cancers, including breast cancer and prostate cancer, contribute significantly to the pain and disability often associated with later stages of malignant disease. Although bisphosphonates have demonstrated efficacy in the treatment of metastatic bone disease (MBD), identifying patients most likely to develop bone metastases (and thus to benefit from treatment) is a challenge. In recent years, advances in understanding the pathophysiologic underpinnings of bone metastases have led to the discovery of several potential markers for dysregulation of bone coupling. Trials have been conducted to validate these biochemical markers and to explore their possible role in measuring efficacy of bisphosphonate treatment and of other metastatic bone therapies. In no area is this research more important than in the management of breast cancer. Although the value of these bone turnover markers is still unclear, and further research is necessary, results from these recent trials indicate some correlation.

Original languageEnglish (US)
Pages (from-to)20-22
Number of pages3
JournalCancer Treatment Reviews
Volume32
Issue numberSUPPL. 1
DOIs
StatePublished - May 9 2006

Fingerprint

Biomarkers
Breast Neoplasms
Bone and Bones
Diphosphonates
Neoplasm Metastasis
Prostatic Neoplasms
Bone Remodeling
Bone Diseases
Research
Pain
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Lipton, Allan. / Biochemical bone markers in breast cancer. In: Cancer Treatment Reviews. 2006 ; Vol. 32, No. SUPPL. 1. pp. 20-22.
@article{13bbcd38d0e34dea84a5ee2001252e06,
title = "Biochemical bone markers in breast cancer",
abstract = "Summary: Bone metastases, the most common metastatic manifestation of many cancers, including breast cancer and prostate cancer, contribute significantly to the pain and disability often associated with later stages of malignant disease. Although bisphosphonates have demonstrated efficacy in the treatment of metastatic bone disease (MBD), identifying patients most likely to develop bone metastases (and thus to benefit from treatment) is a challenge. In recent years, advances in understanding the pathophysiologic underpinnings of bone metastases have led to the discovery of several potential markers for dysregulation of bone coupling. Trials have been conducted to validate these biochemical markers and to explore their possible role in measuring efficacy of bisphosphonate treatment and of other metastatic bone therapies. In no area is this research more important than in the management of breast cancer. Although the value of these bone turnover markers is still unclear, and further research is necessary, results from these recent trials indicate some correlation.",
author = "Allan Lipton",
year = "2006",
month = "5",
day = "9",
doi = "10.1016/S0305-7372(06)80005-8",
language = "English (US)",
volume = "32",
pages = "20--22",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 1",

}

Biochemical bone markers in breast cancer. / Lipton, Allan.

In: Cancer Treatment Reviews, Vol. 32, No. SUPPL. 1, 09.05.2006, p. 20-22.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biochemical bone markers in breast cancer

AU - Lipton, Allan

PY - 2006/5/9

Y1 - 2006/5/9

N2 - Summary: Bone metastases, the most common metastatic manifestation of many cancers, including breast cancer and prostate cancer, contribute significantly to the pain and disability often associated with later stages of malignant disease. Although bisphosphonates have demonstrated efficacy in the treatment of metastatic bone disease (MBD), identifying patients most likely to develop bone metastases (and thus to benefit from treatment) is a challenge. In recent years, advances in understanding the pathophysiologic underpinnings of bone metastases have led to the discovery of several potential markers for dysregulation of bone coupling. Trials have been conducted to validate these biochemical markers and to explore their possible role in measuring efficacy of bisphosphonate treatment and of other metastatic bone therapies. In no area is this research more important than in the management of breast cancer. Although the value of these bone turnover markers is still unclear, and further research is necessary, results from these recent trials indicate some correlation.

AB - Summary: Bone metastases, the most common metastatic manifestation of many cancers, including breast cancer and prostate cancer, contribute significantly to the pain and disability often associated with later stages of malignant disease. Although bisphosphonates have demonstrated efficacy in the treatment of metastatic bone disease (MBD), identifying patients most likely to develop bone metastases (and thus to benefit from treatment) is a challenge. In recent years, advances in understanding the pathophysiologic underpinnings of bone metastases have led to the discovery of several potential markers for dysregulation of bone coupling. Trials have been conducted to validate these biochemical markers and to explore their possible role in measuring efficacy of bisphosphonate treatment and of other metastatic bone therapies. In no area is this research more important than in the management of breast cancer. Although the value of these bone turnover markers is still unclear, and further research is necessary, results from these recent trials indicate some correlation.

UR - http://www.scopus.com/inward/record.url?scp=33646229295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646229295&partnerID=8YFLogxK

U2 - 10.1016/S0305-7372(06)80005-8

DO - 10.1016/S0305-7372(06)80005-8

M3 - Article

VL - 32

SP - 20

EP - 22

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - SUPPL. 1

ER -